Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device Incubation: Challenges in Making the Model Work

This article was originally published in Start Up

Executive Summary

Device incubators have their proponents and detractors, but remain a constant source of company creation. The big question: is this model sustainable?

You may also be interested in...



NDI Medical's Spin-Off Model for Neurostimulation

The neurostimulation market is becoming electric for many large companies looking for major growth opportunities. Worth $1.3 billion in the US in 2009, the neurostimulation market is expected to grow to $2.7 billion by the year 2014. Those robust figures take into account some fourteen different clinical product categories, some of the largest being Alzheimer's disease, chronic pain, depression, epilepsy, obstructive sleep apnea, obesity, and stroke. In fact, that's the beauty of neurostimulation for medical device companies: it offers a single platform technology that can be leveraged over multiple, large product areas. But what model most efficiently helps a company with core expertise in neurostimulation - the knowledge of impulse generators and leads and their interface with nerves, power sources, and controllers - leverage that knowledge over numerous product areas? NDI Medical has its own strategy with a for-profit incubator solely focused on neurostimulation.

NDI Medical's Spin-Off Model for Neurostimulation

The neurostimulation market is becoming electric for many large companies looking for major growth opportunities. Worth $1.3 billion in the US in 2009, the neurostimulation market is expected to grow to $2.7 billion by the year 2014. Those robust figures take into account some fourteen different clinical product categories, some of the largest being Alzheimer's disease, chronic pain, depression, epilepsy, obstructive sleep apnea, obesity, and stroke. In fact, that's the beauty of neurostimulation for medical device companies: it offers a single platform technology that can be leveraged over multiple, large product areas. But what model most efficiently helps a company with core expertise in neurostimulation - the knowledge of impulse generators and leads and their interface with nerves, power sources, and controllers - leverage that knowledge over numerous product areas? NDI Medical has its own strategy with a for-profit incubator solely focused on neurostimulation.

Foundry Offspring Sires First Company

ForSight Labs LLC, the incubator founded in 2005 by The Foundry spun out its first company, Transcend Medical Inc., a company targeting glaucoma. Morgenthaler Ventures and Split Rock Partners teamed up to supply the company's first round of financing.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1131867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel